Truly Translational Sweden AB offers drug development and business development consultancy services.

Our mission is to help our customers to translate preclinical project ideas into efficient experimental plans and conclusive clinical trials.

Truly Translational is founded on solid scientific expertise and almost 100 years experience of drug research & development in both large pharma and biotech. We help our customers to bring drug projects from preclinical in vitro studies and animal models, via common biomarker strategies, into concept testing in patients.

We have solid experience in working with both small and large molecules. Our key therapeutic areas are inflammation, oncology, respiratory diseases, and autoimmune diseases.

As a member of the Medicon Valley Inhalation Consortium we possess access to unique competence and capabilities within inhalation, where Truly Labs offers pre-clinical in vivo inhalation pharmacology services.


With offices at Medicon Village Science Park in Lund, Sweden, Truly Translational is centrally located in the buzzing Medicon Valley area. You can easily visit our facilities as Copenhagen and its international airport is only 30 minutes away.


Truly Translational was founded in 2011 by former AstraZeneca employees with extensive experience from the life science sector including pharmaceutical and biotech companies.

Our experiences span from pre-clinical to early clinical drug discovery and development, and include e.g. expertise in pharmacology, pharmacokinetics and pharmacodynamics, design of in vitro and in vivo studies for both small molecules and biologicals, safety evaluation plans incl. outsourcing and coordination of activities, as well as supporting documentation for CTA submission.

We have worked with project and line management, as well as business development with cross-functional teams in an international environment.

Our aim is to bring projects from in vitro studies and animal models into concept testing in patients.


Our main area of expertise is inflammation and we have R&D experiences from several different therapeutic areas, spanning from pre-clinical research to early clinical development, including pre-clinical pharmacology as well as biomarker and personalized medicine applications. Together with extensive experiences from strategic and operational project management, international environment, cross-functional team work and line management we can translate your pre-clinical project ideas into efficient development plans delivering successful clinical trials.

Therapeutic Areas

  • Inflammation

  • Respiratory

  • Oncology

  • Cardiovascular

  • Autoimmunity

  • Gastointestinal

Strategy & Leadership

  • Strategic Project plans

  • Operational Project Plans

  • Outscourcing

  • Personalized Medicine

  • Patient Segmentation

  • Information Management

  • Business Development


Patrik Holmqvist

Senior Director Software Development at IKEA. M Sc in Computer Science and Engineering from Lund. 15+ years in Pharmaceutical R&D Digital in roles as VP Research Informatics, Novo Nordisk, and Global IT Director, AstraZeneca R&D, in Sweden, UK and Denmark. Delivered Alfa Laval IT transformation programme as Chief Architect.

Karin von Wachenfeldt

CEO and cofounder of Truly Translational Sweden AB. Ph. D. in Immunotechnology from Lund University and Marketing Economist (EFL). Broad experience of early stage pharmaceutical development of small molecules and biopharmaceuticals from BioInvent, Pharmacia Upjohn, Active Biotech and AstraZeneca.

Charlott Brunmark

CSO and cofounder of Truly Translational Sweden AB. Ph. D. in Medical Sciences from Lund University. Broad experience within In vivo pharmacology and pharmaceutical development of small molecules as well as biologics from Pharmacia Upjohn, Active Biotech, Cartela and AstraZeneca.